Riskpilot← Back to searchSign inGet full accessCellaVision AB
ABActiveOrg 5565000998Mobilvägen 12Research and experimental development on natural sciences and engineering · NACE 7210Est. 1994155 employees
Revenue 2024
SEK 555,5M
+6% vs 2023
EBITDA margin
19.8%
-3% vs 2023
Equity ratio
85.5%
Financial strength
Net profit 2024
SEK 93,6M
+4% vs 2023
| Revenue | SEK 555,5M | +6% |
| EBITDA | SEK 110,1M | -3% |
| Net profit | SEK 93,6M | +4% |
| Total assets | SEK 648,7M | +4% |
| Equity | SEK 554,9M | +8% |
| Employees | 155 | — |
Legal name
CellaVision AB
Org number
5565000998
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 december 1994
Share capital
SEK 3 578 000
Employees
155 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av Worning, Mikael Østergaard, Simon Firman tecknas av en av Jönsson, Monica Kristina Østergaard, Simon i förening med två av Armstrong-Denby, Helen Elizabeth Louise Fåhraeus, Lars Christer Fredrik Hjalmarsson, Emil Lars Robert Jarleryd, Ann-Charlotte Wolf, Stefan Karl Dieter Worning, Mikael Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall , med särskild inriktning mot mjukvaruapplikationer för den medicinska marknaden, utveckla, marknadsföra och försälja produkter och system för automatiserad digital mikroskopering, samt bedriva därmed förenlig verksamhet.
Address
Mobilvägen 12
Phone
+46464601600
Email
info@cellavision.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 302 975 | 358 349 | 433 854 | 372 387 | 457 280 | 517 207 | 523 473 | 555 523 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 63 596 | 57 226 | 64 663 | 89 217 | 113 359 | 90 279 | 122 533 | 121 640 | 113 840 | 110 094 |
| Depreciation & amort. | — | — | — | — | — | — | — | — | — | — |
| EBIT | 63 596 | 57 226 | 64 663 | 89 217 | 113 359 | 90 279 | 122 533 | 121 640 | 113 840 | 110 094 |
| Net financials | 186 | 1 723 | −302 | 506 | 3 209 | 9 779 | −3 113 | −8 962 | 78 | 706 |
| Profit before tax | 63 782 | 58 949 | 64 361 | 89 723 | 116 567 | 100 059 | 119 420 | 112 678 | 113 919 | 116 991 |
| Tax | −11 775 | −12 733 | −14 245 | −19 439 | −26 529 | −20 097 | −24 936 | −23 575 | −23 710 | −23 399 |
| Net profit | 52 007 | 46 216 | 50 116 | 70 284 | 90 038 | 79 962 | 94 484 | 89 103 | 90 209 | 93 592 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 205 026 | 228 440 | 251 253 | 302 140 | 471 003 | 502 578 | 608 159 | 622 379 | 624 915 | 648 721 |
| Equity | 166 971 | 177 410 | 191 748 | 226 255 | 280 516 | 360 477 | 437 073 | 478 472 | 515 015 | 554 941 |
| Long-term debt | 0 | 0 | 0 | 0 | 89 207 | 62 935 | 51 537 | 27 247 | 4 957 | 0 |
| Short-term debt | 36 945 | 49 782 | 57 104 | 73 427 | 96 840 | 79 165 | 119 549 | 116 659 | 104 943 | 92 380 |
| Total debt | 36 945 | 49 782 | 57 104 | 73 427 | 186 047 | 142 100 | 171 086 | 143 906 | 109 900 | 92 380 |
EBITDA margin
19.8%
This company
15.8%
Market median
+25% vs market
20152024
Equity ratio
85.5%
This company
38.2%
Market median
+124% vs market
20152024
Return on equity
16.9%
This company
18.4%
Market median
+8% vs market
20152024
Net profit margin
16.8%
This company
8.1%
Market median
+107% vs market
20152024
Asset turnover
0.86×
This company
1.12×
Market median
+23% vs market
20152024
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KA External Signatory | External Signatory | 2020 | — | — |
MC External Signatory | External Signatory | 2020 | — | — |
LM External Signatory | External Signatory | 2020 | — | — |
MS Chief Auditor | Chief Auditor | 2020 | — | — |
ZR Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
JE Chief Auditor | Chief Auditor | 2021 | — | — |
SØ Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
KT Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
MK External Signatory | External Signatory | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2026 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CellaVision AB (this company)
Cellavision Canada IncRal Diagnostics SasCellavision Japan KkClearbridge Biophotonics Pte. LtdCellavision IncCellavision IncCELLAVISION INCRAL DIAGNOSTICS SASCELLAVISION JAPAN KKCELLAVISION CANADA INCBoard members of CellaVision AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Adam Peter Morell | External Signatory | 0 companies |
| Maria Christina Sophia Hägglund Morin | External Signatory | 0 companies |
| Lars Magnus Blixt | External Signatory | 0 companies |
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Zlatko Rihter | Chief Executive Officer | 0 companies |
| Jonas Ebbe Nihlberg | Chief Auditor | 0 companies |
| Simon Østergaard | Chief Executive Officer | 0 companies |
| Kent Thomas Bertil Stråhlén | Chief Executive Officer | 0 companies |
| Monica Kristina Jönsson | External Signatory | 0 companies |
| Lars Christer Fredrik Fåhraeus | Board of Directors | 0 companies |
| J Markus Jonasson Kristoffersson | Board of Directors | 0 companies |
| Anna Malm Bernsten | Board of Directors | 0 companies |
| Helen Elizabeth Louise Armstrong-Denby | Board of Directors | 0 companies |
| Emil Lars Robert Hjalmarsson | Board of Directors | 0 companies |
| Niklas Prager | Board of Directors | 0 companies |
| Mikael Worning | Chairman | 0 companies |
| Carina Madlene Jeanette Bengtsson | Board of Directors | 0 companies |
| Lars Gunnar Brun Hansen | Deputy Board Member | 0 companies |
| Stefan Karl Dieter Wolf | Board of Directors | 0 companies |
| Sven Gustav Sören Mellstig | Chairman | 0 companies |
| Ann-Charlotte Jarleryd | Board of Directors | 0 companies |
| Åsa Suzanne Hedin | Board of Directors | 0 companies |